- Home
- WNW vs RNAZ Comparison
WNW vs RNAZ Comparison
Compare WNW & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- RNAZ
- Stock Information
- Founded
- WNW 2015
- RNAZ 2016
- Country
- WNW China
- RNAZ United States
- Employees
- WNW N/A
- RNAZ N/A
- Industry
- WNW Catalog/Specialty Distribution
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- WNW Consumer Discretionary
- RNAZ Health Care
- Exchange
- WNW Nasdaq
- RNAZ Nasdaq
- Market Cap
- WNW 5.7M
- RNAZ 6.1M
- IPO Year
- WNW 2020
- RNAZ 2021
- Fundamental
- Price
- WNW $1.87
- RNAZ $11.74
- Analyst Decision
- WNW
- RNAZ Strong Buy
- Analyst Count
- WNW 0
- RNAZ 1
- Target Price
- WNW N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- WNW 61.5K
- RNAZ 239.7K
- Earning Date
- WNW 08-05-2025
- RNAZ 08-13-2025
- Dividend Yield
- WNW N/A
- RNAZ N/A
- EPS Growth
- WNW N/A
- RNAZ N/A
- EPS
- WNW 9.06
- RNAZ N/A
- Revenue
- WNW $158,485.00
- RNAZ N/A
- Revenue This Year
- WNW N/A
- RNAZ N/A
- Revenue Next Year
- WNW N/A
- RNAZ N/A
- P/E Ratio
- WNW $0.21
- RNAZ N/A
- Revenue Growth
- WNW N/A
- RNAZ N/A
- 52 Week Low
- WNW $0.95
- RNAZ $6.15
- 52 Week High
- WNW $70.00
- RNAZ $739.20
- Technical
- Relative Strength Index (RSI)
- WNW 53.30
- RNAZ 67.96
- Support Level
- WNW $1.82
- RNAZ $9.02
- Resistance Level
- WNW $1.90
- RNAZ $17.24
- Average True Range (ATR)
- WNW 0.08
- RNAZ 1.28
- MACD
- WNW 0.00
- RNAZ 0.31
- Stochastic Oscillator
- WNW 73.91
- RNAZ 40.21
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.